108 related articles for article (PubMed ID: 23570202)
21. Hirudins: from leeches to man.
Wallis RB
Semin Thromb Hemost; 1996; 22(2):185-96. PubMed ID: 8807716
[TBL] [Abstract][Full Text] [Related]
22. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
Tanaka KA; Szlam F; Sun HY; Taketomi T; Levy JH
Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368
[TBL] [Abstract][Full Text] [Related]
23. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
Reverter JC; Béguin S; Kessels H; Kumar R; Hemker HC; Coller BS
J Clin Invest; 1996 Aug; 98(3):863-74. PubMed ID: 8698879
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin.
Keating FK; Dauerman HL; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2006; 118(3):361-9. PubMed ID: 16139336
[TBL] [Abstract][Full Text] [Related]
26. The role of bivalirudin in percutaneous coronary intervention.
Topol EJ
J Invasive Cardiol; 2000 Dec; 12 Suppl F():1F. PubMed ID: 11156726
[No Abstract] [Full Text] [Related]
27. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
[TBL] [Abstract][Full Text] [Related]
28. Direct thrombin inhibitors (part 2 of 2).
Arora UK; Dhir M
J Invasive Cardiol; 2005 Feb; 17(2):85-91. PubMed ID: 15687531
[No Abstract] [Full Text] [Related]
29. Mechanisms of antithrombotic drugs.
Thiagarajan P; Wu KK
Adv Pharmacol; 1999; 46():297-324. PubMed ID: 10332506
[No Abstract] [Full Text] [Related]
30. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
31. [Direct thrombin inhibitors in coronary angioplasty. Value of bivalirudin ].
Coste P; Labèque JN; Leroux L; Laplace G; Jaïs C; Gerbaud E; Dos Santos P
Arch Mal Coeur Vaiss; 2006 Feb; 99 Spec no.3():11-5. PubMed ID: 16553238
[TBL] [Abstract][Full Text] [Related]
32. An overview of antithrombins in peripheral vascular interventions.
Shammas NW
J Invasive Cardiol; 2004 Aug; 16(8):440-3. PubMed ID: 15282423
[No Abstract] [Full Text] [Related]
33. Dynamic thrombosis and thrombolysis. Role of antithrombins.
Chesebro JH; Fuster V
Circulation; 1991 May; 83(5):1815-7. PubMed ID: 2022032
[No Abstract] [Full Text] [Related]
34. The scientific basis for combined platelet and thrombin-directed pharmacotherapy in acute coronary syndromes.
Becker RC
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E19-24;discussion E25-8. PubMed ID: 11156725
[TBL] [Abstract][Full Text] [Related]
35. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition.
Ferguson JJ; Waly HM; Wilson JM
Eur Heart J; 1998 Apr; 19 Suppl D():D3-9. PubMed ID: 9597517
[TBL] [Abstract][Full Text] [Related]
36. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
[TBL] [Abstract][Full Text] [Related]
37. Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin.
Harding SA; Din JN; Sarma J; Josephs DH; Fox KA; Newby DE
Heart; 2006 Nov; 92(11):1635-8. PubMed ID: 16709700
[TBL] [Abstract][Full Text] [Related]
38. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
39. Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention.
Watson K; Seybert AL; Saul MI; Lee JS; Kane-Gill SL
Pharmacotherapy; 2007 May; 27(5):647-56. PubMed ID: 17461699
[TBL] [Abstract][Full Text] [Related]
40. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
